



MAT Biopharma announced completion of enrollment for Ferritarg®

Evry, France, September 11 2008 MAT Biopharma today announced the completion of enrollment in the Phase I/II clinical trial for Ferritarg® in patients with relapsed or refractory Hodgkin's disease.

The objective of this study is to assess the safety and determine the MTD. Results from this study are expected in Q4 08 and MAT Biopharma projects to initiate the pivotal phase III in 2009.

Jean Kadouche, Chief Executive Officer commented, "We are very pleased, the completion of patient enrollment in this trial marks a significant milestone for patients and the company", he added, "Preliminary efficacy results are promising and encouraging".

Frédéric Gomez, Head of Corporate and Business Development noted, "MAT Biopharma's pipeline continues to mature. Data from this study will enable us to finalize the most appropriate and efficient development strategy for Ferritarg®, leading discussion with investigators and clinicians both in Europe and in the US".

-Ends-

About Hodgkin's disease

Hodgkin's disease, also known as Hodgkin's lymphoma, is a rare cancer of the lymphatic system. In Hodgkin's disease, cells in the lymphatic system grow abnormally and may spread beyond the lymphatic system. As Hodgkin's disease progresses, it compromises your body's ability to fight infection.

Hodgkin's disease most commonly affects people between the ages of 15 and 40 and people older than age 55. It's one of two common types of cancers of the lymphatic system. In the United States in 2004, there were about 7,880 new cases of Hodgkin's disease.

About MAT Biopharma.

MAT Biopharma is a privately held biopharmaceutical company focused on the development and commercialization of antibody based therapeutics for the treatment of haematological cancers and some solid tumors

Note: Ferritarg® is a trademark of MAT Biopharma

Source : MAT Biopharma

Contact:

Frédéric Gomez, Head of Corporate and Business Development,
f.gomez@matbiopharma.fr